Cost-of-illness of patients with systemic sclerosis in a tertiary care centre

Abstract

The cost-of-illness of SSc is high with a dominance of productivity loss related costs. Moreover, the disease activity is an important cost driver.

Socio-economic burden of rare diseases: A systematic review of cost of illness evidence

“…up to 216% of direct costs in the case of scleroderma. All evidence on scleroderma suggests indirect exceeding direct costs (30,105), but in all other conditions where evidence is available the indirect costs amount to less than direct costs. In some cases, direct and indirect costs can be traded off against each other, as in haemophilia care, where patients treated prophylactically incur higher direct costs as a result of factor use but avoid more hospitalizations and thus disruptions to their daily life and work pattern (75).…”

Social/economic costs and health-related quality of life in patients with rare diseases in Europe

“…Although some countryspecific research on a limited set of rare diseases has been done on HRQOL and cost-of-illness [8][9][10][11][12], cross-national research on the socio-economic impact of rare diseases is still lacking in the EU.…”

Quality of life in systemic sclerosis

“…Also mouth disability, reduced mouth opening, altered dentition, speaking difficulties and sicca syndrome could influence employment status in SSc [33], especially in those jobs requiring public contact or talking. Higher costs in SSc patients were strongly associated with greater disease severity, poor health status, younger age, lower education [34,41] and patient's perception of health status [42]. According to Minier et al [42], disease duration has no significant impact on costs.…”